Lipid Metabolism Disorders  >>  niacin extended-release formulation  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
niacin extended-release formulation / Generic mfg.
NCT00533312: MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

Completed
2
407
NA
Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks, MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks, Comparator : niacin / Duraton of Treatment: 4 Weeks
Merck Sharp & Dohme LLC
Hypercholesterolemia
07/05
01/07
CENTAUR, NCT00728910: Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (): A Feasibility Study

Completed
2
25
US
Atorvastatin, Lipitor, ABT335, Trilipex, ER Niacin, Niaspan
University of Pennsylvania, Abbott
Dyslipidemia
08/09
08/09

Download Options